Table 1—

Subject characteristics

ControlsPatients
AllNon-CFRDCFRD
Subjects n26503713
Age yrs28.4±5.728.0±8.226.5±7.932.2±8.1
Sex male/female n14/1233/1724/139/4
Height m1.74±0.11.70±0.11.71±0.11.68±0.1
BMI kg·m−222.2±1.722.2±3.121.9±3.022.9±3.5
Total FFMI# kg·m−218.2±1.818.1±2.618.0±2.618.3±2.6
WHR0.80±0.060.85±0.08*0.86±0.06*0.83±0.13
FEV1 % pred97.4±8.565.1±21.2**69.4±22.0**52.9±12.6**,¶¶
FVC % pred97.5±10.479.6±18.6**83.9±18.9**67.2±10.6**,¶¶
Physical activity MET39 (33–62)42 (29–77)42 (29–77)40 (30–63)
Biochemical measurements
Total cholesterol mmol·L−14.5±0.73.7±0.7**3.7±0.7**3.9±1.0
Cholesterol ratio TC/HDL3.1±0.73.0±0.72.9±0.83.0±0.7
Triglyceride mmol·L−10.7±0.30.9±0.3*0.9±0.30.9±0.3
Fasting glucose mmol·L−15.1±1.15.4±1.34.8±1.17.5±1.5**,¶¶
CRP mg·L−10.4±3.92.7±4.8**1.9±4.7**7.4±3.3**,¶¶
GFR mL·min−1109.7±15.495.5±18.7**95.9±18.5**94.3±19.9*
  • Data presented as mean±sd or median (range), unless otherwise stated. Fasting glucose and C-reactive protein (CRP) are presented as geometric mean±sd. CFRD: cystic fibrosis-related diabetes; BMI: body mass index; FFMI: fat-free mass index; WHR: waist-to-hip ratio; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; MET: metabolic equivalent of task; TC: total cholesterol; HDL: high density lipoprotein; GFR: glomerular filtration rate. #: in 48 patients. *: p<0.05, and **: p<0.01 difference from controls; : p<0.05, and ¶¶: p<0.01 difference from non-diabetic patients.